Suppr超能文献

肿瘤抑制因子hsa-miR-145的恢复可抑制表皮生长因子受体突变的肺腺癌患者的癌细胞生长。

Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation.

作者信息

Cho William C S, Chow Andrew S C, Au Joseph S K

机构信息

Department of Clinical Oncology, Room 1305, 3/F, Block R, Queen Elizabeth Hospital, 30 Gascoigne Road, Kowloon, Hong Kong.

出版信息

Eur J Cancer. 2009 Aug;45(12):2197-206. doi: 10.1016/j.ejca.2009.04.039. Epub 2009 Jun 1.

Abstract

BACKGROUND

In Hong Kong, about 30% of non-small cell lung cancer patients have never smoked tobacco. Among women, 83% are never-smokers and their histological type is invariably adenocarcinoma with 70% incidence of epidermal growth factor receptor (EGFR) mutation. The present study focuses on the microRNA (miRNA) expression profiles of this important subset of lung cancer.

METHODS

Paired samples collected from the lung cancer tissue and adjacent normal lung parenchyma of 10 non-smoking patients with lung adenocarcinoma were profiled by miRNA microarray. Results were validated by quantitative reverse transcription polymerase chain reaction. Transfected cell viability assays were applied to determine the effects of candidate miRNAs on lung cancer cells.

RESULTS

Comparing paired lung cancer tissue with adjacent normal lung parenchyma, hsa-miR-126*, hsa-miR-145, hsa-miR-21, hsa-miR-182, hsa-miR-183 and hsa-miR-210 were found to be the most differentially expressed miRNAs. Most interestingly, an obvious inhibition of cell growth was observed in the EGFR mutant lung adenocarcinoma after transfection of hsa-pre-miR-145.

CONCLUSIONS

Our study is the first report to connect miR-182 to lung cancer. Our results also show that restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in EGFR mutant lung adenocarcinoma. Further study on these specific differentially expressed miRNAs may provide important information on peculiar tumourigenetic pathways and may identify useful biomarkers.

摘要

背景

在香港,约30%的非小细胞肺癌患者从不吸烟。在女性患者中,83%为从不吸烟者,其组织学类型均为腺癌,表皮生长因子受体(EGFR)突变发生率为70%。本研究聚焦于这一重要肺癌亚组的微小RNA(miRNA)表达谱。

方法

对10例非吸烟肺腺癌患者的肺癌组织及相邻正常肺实质采集配对样本,采用miRNA微阵列进行分析。结果通过定量逆转录聚合酶链反应进行验证。应用转染细胞活力测定法确定候选miRNA对肺癌细胞的影响。

结果

将配对的肺癌组织与相邻正常肺实质进行比较,发现hsa-miR-126*、hsa-miR-145、hsa-miR-21、hsa-miR-182、hsa-miR-183和hsa-miR-210是差异表达最显著的miRNA。最有趣的是,转染hsa-pre-miR-145后,在EGFR突变型肺腺癌中观察到细胞生长明显受到抑制。

结论

我们的研究是首次将miR-182与肺癌联系起来的报告。我们的结果还表明,肿瘤抑制因子hsa-miR-145的恢复可抑制EGFR突变型肺腺癌中的癌细胞生长。对这些特异性差异表达的miRNA进行进一步研究,可能会为独特的肿瘤发生途径提供重要信息,并可能识别出有用的生物标志物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验